Fig. 1

Prognostic value of CD13 expression for glioma patients. (A-D) Kaplan-Meier curves for overall survival (OS) (n = 666; A) and for progression-free survival (PFS) (n = 670; B) of glioma patients determined by TCGA database. Kaplan-Meier curves for OS ascertained by CGGA325 database (n = 313; C) and CGGA693 database (n = 657; D). (E-H) ROC (receiver operating characteristic) curves for CD13 expression as a prognostic marker of overall survival (n = 666; E) and PFS (n = 670; F) generated by TCGA database. ROC curves for CD13 expression as a prognostic marker of overall survival determined by CGGA325 database (n = 313; G) and CGGA693 database (n = 657; H). (I-N) CD13 expression classified by age of patients (I), glioma subtype (J; CL: classical; ME: mesenchymal; NE: neural; PN: proneural), glioma grade (K), IDH mutation status (L), MGMT methylation status (M), and 1p19q codeletion status (N) ascertained by TCGA database (n = 450). (O,P) Univariate (O) and multivariate (P) Cox regression analyses of CD13 expression (n = 447; analyzed data of TCGA database). ***P < 0.001 (I, L-N, unpaired Student´s t test; J,K, ANOVA and Bonferroni correction)